TY - JOUR T1 - Remission in Gout: Concepts From a Patient Perspective JF - The Journal of Rheumatology JO - J Rheumatol SP - 242 LP - 243 DO - 10.3899/jrheum.211285 VL - 49 IS - 3 AU - Puja Khanna Y1 - 2022/03/01 UR - http://www.jrheum.org/content/49/3/242.abstract N2 - Any human who has ever experienced an acute gout flare understands how painful and debilitating this condition is. Unfortunately, due to the episodic nature of these acute flares that occur randomly due to transient fluctuations in urate levels, patients often underreport these attacks. This turns into a tragedy—patients are left untreated and develop chronic gouty arthritis where pain-free periods are infrequent and joint damage is abundant. The holy grail in clinical trials, whether acute or chronic gout, has been to understand the various nuances of adherence because we know that it leads to prevention and perhaps remission: how long can a patient stay flare free, how do we quantify it, and what measures should we use?Despite the increase in the number of gout cases,1 the disease is equally mismanaged in primary care and the rheumatology subspecialty. This is evident in the literature, with suboptimal dosing of urate-lowering drugs, intolerance to therapy, or poor patient compliance. Guidelines across the globe have highlighted the gaps in care and the poor quality of life. Gout is considered the most treatable arthritis in the Western World, with the pathophysiology directly related to uric acid metabolism and effective medications available to treat both acute episodes … Address correspondence to Dr. P. Khanna, Division of Rheumatology, Department of Internal Medicine, University of Michigan & AAVAMC, 300 North Ingalls, Ste 7C27, Ann Arbor, MI 48109-5422, USA. Email: pkhanna{at}umich.edu. ER -